<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39408792</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>28</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Immune Profile in COVID-19: Unveiling T<sub>R3-56</sub> Cells in SARS-CoV-2 Infection.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10465</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms251910465</ELocationID><Abstract><AbstractText>The emergence of COronaVIrus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), presented a global health challenge since its identification in December 2019. With clinical manifestations ranging from mild respiratory symptoms to severe multi-organ dysfunction, COVID-19 continues to affect populations worldwide. The complex interactions between SARS-CoV-2 variants and the human immune system are crucial for developing effective therapies, vaccines, and preventive measures. Understanding these immune responses highlights the intricate nature of COVID-19 pathogenesis. This retrospective study analyzed, by flow cytometry approach, a cohort of patients infected with SARS-CoV-2 during the initial pandemic waves from 2020 to 2021. It focused on untreated individuals at the time of hospital admission and examined the presence of T<sub>R3-56</sub> cells in their immune profiles during the anti-viral immune response. Our findings provide additional insights into the complex immunological dynamics of SARS-CoV-2 infection and highlight the potential role of T<sub>R3-56</sub> cells as crucial components of the immune response. We suggest that T<sub>R3-56</sub> cells could serve as valuable biomarkers for identifying more severe cases of COVID-19, aiding in the assessment and management of the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carriero</LastName><ForeName>Flavia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze della Salute, Università degli Studi della Basilicata, 85100 Potenza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubino</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-5646-2795</Identifier><AffiliationInfo><Affiliation>Dipartimento di Scienze Mediche Traslazionali, Università di Napoli "Federico II", 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gelzo</LastName><ForeName>Monica</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1500-0746</Identifier><AffiliationInfo><Affiliation>CEINGE-Biotecnologie Avanzate Franco Salvatore, 80131 Naples, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scalia</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>CEINGE-Biotecnologie Avanzate Franco Salvatore, 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raia</LastName><ForeName>Maddalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CEINGE-Biotecnologie Avanzate Franco Salvatore, 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciccozzi</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3866-9239</Identifier><AffiliationInfo><Affiliation>Unità di Epidemiologia e Statistica Medica, Università Campus Biomedico, 00128 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gentile</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-5199-8451</Identifier><AffiliationInfo><Affiliation>Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli Federico II, 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinchera</LastName><ForeName>Biagio</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli Federico II, 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castaldo</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>CEINGE-Biotecnologie Avanzate Franco Salvatore, 80131 Naples, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruggiero</LastName><ForeName>Giuseppina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Mediche Traslazionali, Università di Napoli "Federico II", 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terrazzano</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3556-6891</Identifier><AffiliationInfo><Affiliation>Dipartimento di Scienze della Salute, Università degli Studi della Basilicata, 85100 Potenza, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PRIN 2022 project code 2022YZCBKX</GrantID><Agency>Italian Ministry for University and Research</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">COronaVIrus Disease 2019</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Severe acute respiratory syndrome coronavirus 2</Keyword><Keyword MajorTopicYN="N">TR3-56</Keyword><Keyword MajorTopicYN="N">immune regulation</Keyword><Keyword MajorTopicYN="N">immune regulatory cell phenotypes</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39408792</ArticleId><ArticleId IdType="pmc">PMC11477006</ArticleId><ArticleId IdType="doi">10.3390/ijms251910465</ArticleId><ArticleId IdType="pii">ijms251910465</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cevik M., Bamford C., Ho A. COVID-19 pandemic—A focused review for clinicians. Clin. Microbiol. Infect. 2020;26:842–847. doi: 10.1016/j.cmi.2020.04.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.04.023</ArticleId><ArticleId IdType="pmc">PMC7182753</ArticleId><ArticleId IdType="pubmed">32344166</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Liu Q., Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J. Med. Virol. 2020;92:418–423. doi: 10.1002/jmv.25681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25681</ArticleId><ArticleId IdType="pmc">PMC7167049</ArticleId><ArticleId IdType="pubmed">31967327</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A., Ahmad Farouk I., Lal S.K. COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention. Viruses. 2021;13:202. doi: 10.3390/v13020202.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13020202</ArticleId><ArticleId IdType="pmc">PMC7911532</ArticleId><ArticleId IdType="pubmed">33572857</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Guo H., Zhou P., Shi Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021;19:141–154. doi: 10.1038/s41579-020-00459-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Chams N., Chams S., Badran R., Shams A., Araji A., Raad M., Mukhopadhyay S., Stroberg E., Duval E.J., Barton L.M., et al. COVID-19: A Multidisciplinary Review. Front. Public Health. 2020;8:383. doi: 10.3389/fpubh.2020.00383.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2020.00383</ArticleId><ArticleId IdType="pmc">PMC7403483</ArticleId><ArticleId IdType="pubmed">32850602</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett A.D.T., Titball R.W., MacAry P.A., Rupp R.E., von Messling V., Walker D.H., Fanget N.V.J. The rapid progress in COVID vaccine development and implementation. NPJ Vaccines. 2022;7:20. doi: 10.1038/s41541-022-00442-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-022-00442-8</ArticleId><ArticleId IdType="pmc">PMC8831501</ArticleId><ArticleId IdType="pubmed">35145102</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaku Y., Okumura K., Padilla-Blanco M., Kosugi Y., Uriu K., Hinay A.A.J., Chen L., Plianchaisuk A., Kobiyama K., Ishii K.J., et al. Virological characteristics of the SARS-CoV-2 JN.1 variant. Lancet Infect. Dis. 2024;24:e82. doi: 10.1016/S1473-3099(23)00813-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00813-7</ArticleId><ArticleId IdType="pubmed">38184005</ArticleId></ArticleIdList></Reference><Reference><Citation>Scialo F., Daniele A., Amato F., Pastore L., Matera M.G., Cazzola M., Castaldo G., Bianco A. ACE2: The Major Cell Entry Receptor for SARS-CoV-2. Lung. 2020;198:867–877. doi: 10.1007/s00408-020-00408-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00408-020-00408-4</ArticleId><ArticleId IdType="pmc">PMC7653219</ArticleId><ArticleId IdType="pubmed">33170317</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapir T., Averch Z., Lerman B., Bodzin A., Fishman Y., Maitra R. COVID-19 and the Immune Response: A Multi-Phasic Approach to the Treatment of COVID-19. Int. J. Mol. Sci. 2022;23:8606. doi: 10.3390/ijms23158606.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23158606</ArticleId><ArticleId IdType="pmc">PMC9369212</ArticleId><ArticleId IdType="pubmed">35955740</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M., Blish C.A., Sallusto F., Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375:1122–1127. doi: 10.1126/science.abm8108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm8108</ArticleId><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Wang Y., Sun Q., Knopf J., Herrmann M., Lin L., Jiang J., Shao C., Li P., He X., et al. Immune response in COVID-19: What is next? Cell Death Differ. 2022;29:1107–1122. doi: 10.1038/s41418-022-01015-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-022-01015-x</ArticleId><ArticleId IdType="pmc">PMC9110941</ArticleId><ArticleId IdType="pubmed">35581387</ArticleId></ArticleIdList></Reference><Reference><Citation>Maison D.P., Deng Y., Gerschenson M. SARS-CoV-2 and the host-immune response. Front. Immunol. 2023;14:1195871. doi: 10.3389/fimmu.2023.1195871.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1195871</ArticleId><ArticleId IdType="pmc">PMC10315470</ArticleId><ArticleId IdType="pubmed">37404823</ArticleId></ArticleIdList></Reference><Reference><Citation>Sievers B.L., Cheng M.T.K., Csiba K., Meng B., Gupta R.K. SARS-CoV-2 and innate immunity: The good, the bad, and the “goldilocks”. Cell Mol. Immunol. 2024;21:171–183. doi: 10.1038/s41423-023-01104-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-023-01104-y</ArticleId><ArticleId IdType="pmc">PMC10805730</ArticleId><ArticleId IdType="pubmed">37985854</ArticleId></ArticleIdList></Reference><Reference><Citation>Scialo F., Vitale M., Daniele A., Nigro E., Perrotta F., Gelzo M., Iadevaia C., Cerqua F.S., Costigliola A., Allocca V., et al. SARS-CoV-2: One Year in the Pandemic. What Have We Learned, the New Vaccine Era and the Threat of SARS-CoV-2 Variants. Biomedicines. 2021;9:611. doi: 10.3390/biomedicines9060611.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9060611</ArticleId><ArticleId IdType="pmc">PMC8226851</ArticleId><ArticleId IdType="pubmed">34072088</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelzo M., Cacciapuoti S., Pinchera B., De Rosa A., Cernera G., Scialò F., Comegna M., Mormile M., Fabbrocini G., Parrella R., et al. Further Findings Concerning Endothelial Damage in COVID-19 Patients. Biomolecules. 2021;11:1368. doi: 10.3390/biom11091368.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11091368</ArticleId><ArticleId IdType="pmc">PMC8468524</ArticleId><ArticleId IdType="pubmed">34572581</ArticleId></ArticleIdList></Reference><Reference><Citation>Maucourant C., Filipovic I., Ponzetta A., Aleman S., Cornillet M., Hertwig L., Strunz B., Lentini A., Reinius B., Brownlie D., et al. Natural killer cell immunotypes related to COVID-19 disease severity. Sci. Immunol. 2020;5:eabd6832. doi: 10.1126/sciimmunol.abd6832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abd6832</ArticleId><ArticleId IdType="pmc">PMC7665314</ArticleId><ArticleId IdType="pubmed">32826343</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermens J.M., Kesmir C. Role of T cells in severe COVID-19 disease, protection, and long term immunity. Immunogenetics. 2023;75:295–307. doi: 10.1007/s00251-023-01294-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00251-023-01294-9</ArticleId><ArticleId IdType="pmc">PMC9905767</ArticleId><ArticleId IdType="pubmed">36752852</ArticleId></ArticleIdList></Reference><Reference><Citation>Zielinski C.E. T helper cell subsets: Diversification of the field. Eur. J. Immunol. 2023;52:2250218. doi: 10.1002/eji.202250218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.202250218</ArticleId><ArticleId IdType="pubmed">36792132</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohd Zawawi Z., Kalyanasundram J., Mohd Zain R., Thayan R., Basri D.F., Yap W.B. Prospective Roles of Tumor Necrosis Factor-Alpha (TNF-α) in COVID-19: Prognosis, Therapeutic and Management. Int. J. Mol. Sci. 2023;24:6142. doi: 10.3390/ijms24076142.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24076142</ArticleId><ArticleId IdType="pmc">PMC10094668</ArticleId><ArticleId IdType="pubmed">37047115</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacciapuoti S., De Rosa A., Gelzo M., Megna M., Raia M., Pinchera B., Pontarelli A., Scotto R., Scala E., Scarano F., et al. Immunocytometric analysis of COVID patients: A contribution to personalized therapy? Life Sci. 2020;261:118355. doi: 10.1016/j.lfs.2020.118355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.118355</ArticleId><ArticleId IdType="pmc">PMC7456265</ArticleId><ArticleId IdType="pubmed">32871183</ArticleId></ArticleIdList></Reference><Reference><Citation>van Loo G., Bertrand M.J.M. Death by TNF: A road to inflammation. Nat. Rev. Immunol. 2023;23:289–303. doi: 10.1038/s41577-022-00792-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00792-3</ArticleId><ArticleId IdType="pmc">PMC9665039</ArticleId><ArticleId IdType="pubmed">36380021</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur S., Bansal Y., Kumar R., Bansal G. A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors. Bioorg. Med. Chem. 2020;28:115327. doi: 10.1016/j.bmc.2020.115327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2020.115327</ArticleId><ArticleId IdType="pubmed">31992476</ArticleId></ArticleIdList></Reference><Reference><Citation>Piscoya A., Parra Del Riego A., Cerna-Viacava R., Rocco J., Roman Y.M., Escobedo A.A., Pasupuleti V., White C.M., Hernandez A.V. Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: A systematic review and meta-analysis. PLoS ONE. 2022;17:e0269368. doi: 10.1371/journal.pone.0269368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0269368</ArticleId><ArticleId IdType="pmc">PMC9165853</ArticleId><ArticleId IdType="pubmed">35657993</ArticleId></ArticleIdList></Reference><Reference><Citation>Saraiva M., O’Garra A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 2010;10:170–181. doi: 10.1038/nri2711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2711</ArticleId><ArticleId IdType="pubmed">20154735</ArticleId></ArticleIdList></Reference><Reference><Citation>Martonik D., Parfieniuk-Kowerda A., Rogalska M., Flisiak R. The Role of Th17 Response in COVID-19. Cells. 2021;10:1550. doi: 10.3390/cells10061550.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10061550</ArticleId><ArticleId IdType="pmc">PMC8235311</ArticleId><ArticleId IdType="pubmed">34205262</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C. Defining the TH17 cell lineage. Nat. Rev. Immunol. 2021;21:618. doi: 10.1038/s41577-021-00596-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00596-x</ArticleId><ArticleId IdType="pubmed">34580449</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Mughales J.A., Al-Mughales T.J., Saadah O.I. Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study. Front. Immunol. 2021;12:705441. doi: 10.3389/fimmu.2021.705441.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.705441</ArticleId><ArticleId IdType="pmc">PMC8446649</ArticleId><ArticleId IdType="pubmed">34539635</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman H.W., Letovsky S., Meyer W.A., 3rd, Gillim L., Assimon M.M., Kabelac C.A., Kroner J.W., Reynolds S.L., Eisenberg M. SARS-CoV-2 spike-protein targeted serology test results and their association with subsequent COVID-19-related outcomes. Front. Public Health. 2023;11:1193246. doi: 10.3389/fpubh.2023.1193246.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1193246</ArticleId><ArticleId IdType="pmc">PMC10407563</ArticleId><ArticleId IdType="pubmed">37559735</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortese P., Amato F., Davino A., De Franchis R., Esposito S., Zollo I., Di Domenico M., Solito E., Zarrilli F., Gentile L., et al. The Immune Response to SARS-CoV-2 Vaccine in a Cohort of Family Pediatricians from Southern Italy. Cells. 2023;12:1447. doi: 10.3390/cells12111447.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12111447</ArticleId><ArticleId IdType="pmc">PMC10252549</ArticleId><ArticleId IdType="pubmed">37296568</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragab D., Salah Eldin H., Taeimah M., Khattab R., Salem R. The COVID-19 Cytokine Storm; What We Know So Far. Front. Immunol. 2020;11:1446. doi: 10.3389/fimmu.2020.01446.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01446</ArticleId><ArticleId IdType="pmc">PMC7308649</ArticleId><ArticleId IdType="pubmed">32612617</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelzo M., Cacciapuoti S., Pinchera B., De Rosa A., Cernera G., Scialò F., Mormile M., Fabbrocini G., Parrella R., Gentile I., et al. Prognostic Role of Neutrophil to Lymphocyte Ratio in COVID-19 Patients: Still Valid in Patients That Had Started Therapy? Front. Public Health. 2021;9:664108. doi: 10.3389/fpubh.2021.664108.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2021.664108</ArticleId><ArticleId IdType="pmc">PMC8239130</ArticleId><ArticleId IdType="pubmed">34211953</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y., Xie C., Ma K., Shang K., Wang W., et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis. 2020;71:762–768. doi: 10.1093/cid/ciaa248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa248</ArticleId><ArticleId IdType="pmc">PMC7108125</ArticleId><ArticleId IdType="pubmed">32161940</ArticleId></ArticleIdList></Reference><Reference><Citation>Carriero F., Rubino V., Leone S., Montanaro R., Brancaleone V., Ruggiero G., Terrazzano G. Regulatory TR3-56 Cells in the Complex Panorama of Immune Activation and Regulation. Cells. 2023;12:2841. doi: 10.3390/cells12242841.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12242841</ArticleId><ArticleId IdType="pmc">PMC10742044</ArticleId><ArticleId IdType="pubmed">38132162</ArticleId></ArticleIdList></Reference><Reference><Citation>Devenish L.P., Mhlanga M.M., Negishi Y. Immune Regulation in Time and Space: The Role of Local- and Long-Range Genomic Interactions in Regulating Immune Responses. Front. Immunol. 2021;12:662565. doi: 10.3389/fimmu.2021.662565.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.662565</ArticleId><ArticleId IdType="pmc">PMC8144502</ArticleId><ArticleId IdType="pubmed">34046034</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaguchi S., Miyara M., Costantino C.M., Hafler D.A. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 2010;10:490–500. doi: 10.1038/nri2785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2785</ArticleId><ArticleId IdType="pubmed">20559327</ArticleId></ArticleIdList></Reference><Reference><Citation>Panduro M., Benoist C., Mathis D. Tissue Tregs. Annu. Rev. Immunol. 2016;34:609–633. doi: 10.1146/annurev-immunol-032712-095948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-032712-095948</ArticleId><ArticleId IdType="pmc">PMC4942112</ArticleId><ArticleId IdType="pubmed">27168246</ArticleId></ArticleIdList></Reference><Reference><Citation>Makino Y., Kanno R., Ito T., Higashino K., Taniguchi M. Predominant expression of invariant V alpha 14+ TCR alpha chain in NK1.1+ T cell populations. Int. Immunol. 1995;7:1157–1161. doi: 10.1093/intimm/7.7.1157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/7.7.1157</ArticleId><ArticleId IdType="pubmed">8527413</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond K.J., Pelikan S.B., Crowe N.Y., Randle-Barrett E., Nakayama T., Taniguchi M., Smyth M.J., van Driel I.R., Scollay R., Baxter A.G., et al. NKT cells are phenotypically and functionally diverse. Eur. J. Immunol. 1999;29:3768–3781. doi: 10.1002/(SICI)1521-4141(199911)29:11&lt;3768::AID-IMMU3768&gt;3.0.CO;2-G.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1521-4141(199911)29:11&lt;3768::AID-IMMU3768&gt;3.0.CO;2-G</ArticleId><ArticleId IdType="pubmed">10556834</ArticleId></ArticleIdList></Reference><Reference><Citation>Godfrey D.I., MacDonald H.R., Kronenberg M., Smyth M.J., Van Kaer L. NKT cells: What’s in a name? Nat. Rev. Immunol. 2004;4:231–237. doi: 10.1038/nri1309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1309</ArticleId><ArticleId IdType="pubmed">15039760</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadola S.D., Dulphy N., Salio M., Cerundolo V. Valpha24-JalphaQ-independent, CD1d-restricted recognition of α- galactosylceramide by human CD4+ and CD8 αβ+ T lymphocytes. J. Immunol. 2002;168:5514–5520. doi: 10.4049/jimmunol.168.11.5514.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.168.11.5514</ArticleId><ArticleId IdType="pubmed">12023346</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt S., Mattner J. NKT Cells Contribute to the Control of Microbial Infections. Front. Cell Infect. Microbiol. 2021;11:718350. doi: 10.3389/fcimb.2021.718350.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.718350</ArticleId><ArticleId IdType="pmc">PMC8477047</ArticleId><ArticleId IdType="pubmed">34595131</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwen-Smith R.M., Salio M., Cerundolo V. The regulatory role of invariant NKT cells in tumor immunity. Cancer Immunol. Res. 2015;3:425–435. doi: 10.1158/2326-6066.CIR-15-0062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-15-0062</ArticleId><ArticleId IdType="pmc">PMC4430818</ArticleId><ArticleId IdType="pubmed">25941354</ArticleId></ArticleIdList></Reference><Reference><Citation>Kriegsmann K., Kriegsmann M., von Bergwelt-Baildon M., Cremer M., Witzens-Harig M. NKT cells—New players in CAR cell immunotherapy? Eur. J. Haematol. 2018;101:750–757. doi: 10.1111/ejh.13170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.13170</ArticleId><ArticleId IdType="pubmed">30187578</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Kaer L., Wu L. Therapeutic Potential of Invariant Natural Killer T Cells in Autoimmunity. Front. Immunol. 2018;9:519. doi: 10.3389/fimmu.2018.00519.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00519</ArticleId><ArticleId IdType="pmc">PMC5859017</ArticleId><ArticleId IdType="pubmed">29593743</ArticleId></ArticleIdList></Reference><Reference><Citation>Zdrazilova-Dubska L., Valik D., Budinska E., Frgala T., Bacikova L., Demlova R. NKT-like cells are expanded in solid tumor patients. Klin. Onkol. 2012;25((Suppl. S2)):2S21–2S25.</Citation><ArticleIdList><ArticleId IdType="pubmed">23581012</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Yang D., Xu W., Wang Y., Ruan Z., Zhao T., Han J., Wu Y. Tumor-derived soluble MICs impair CD3+CD56+ NKT-like cell cytotoxicity in cancer patients. Immunol. Lett. 2008;120:65–71. doi: 10.1016/j.imlet.2008.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2008.07.001</ArticleId><ArticleId IdType="pubmed">18672004</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J., Zhao X., Wang Z., Wang J., Sun H., Hu Y. High circulating CD3+CD56+CD16+ natural killer-like T cell levels predict a better IVF treatment outcome. J. Reprod. Immunol. 2013;97:197–203. doi: 10.1016/j.jri.2012.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jri.2012.12.006</ArticleId><ArticleId IdType="pubmed">23452704</ArticleId></ArticleIdList></Reference><Reference><Citation>Tajiri K., Shimizu Y., Tsuneyama K., Sugiyama T. Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 2009;21:673–680. doi: 10.1097/MEG.0b013e32831bc3d6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0b013e32831bc3d6</ArticleId><ArticleId IdType="pubmed">19318971</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanackovic D., Nowottne U., Freier E., Weber C.S., Meyer S., Bartels K., Hildebrandt Y., Cao Y., Kröger N., Brunner-Weinzierl M.C., et al. Acute psychological stress increases peripheral blood CD3+CD56+ natural killer T cells in healthy men: Possible implications for the development and treatment of allergic and autoimmune disorders. Stress. 2013;16:421–428. doi: 10.3109/10253890.2013.777702.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10253890.2013.777702</ArticleId><ArticleId IdType="pubmed">23425210</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., Xing C., Dong A., Lin X., Lin Y., Zhu B., He M., Yao R. Numbers and cytotoxicities of CD3+CD56+ T lymphocytes in peripheral blood of patients with acute myeloid leukemia and acute lymphocytic leukemia. Cancer Biol. Ther. 2013;14:916–921. doi: 10.4161/cbt.25938.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cbt.25938</ArticleId><ArticleId IdType="pmc">PMC3926888</ArticleId><ArticleId IdType="pubmed">24030391</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohon P., Porkka K., Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur. J. Haematol. 2010;85:387–398. doi: 10.1111/j.1600-0609.2010.01501.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0609.2010.01501.x</ArticleId><ArticleId IdType="pubmed">20662899</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida J.S., Couceiro P., López-Sejas N., Alves V., Růžičková L., Tarazona R., Solana R., Freitas-Tavares P., Santos-Rosa M., Rodrigues-Santos P. NKT-like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. Front. Immunol. 2019;10:2493. doi: 10.3389/fimmu.2019.02493.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02493</ArticleId><ArticleId IdType="pmc">PMC6817724</ArticleId><ArticleId IdType="pubmed">31695700</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson S.E., Swerdlow S.H., Felgar R.E. Natural killer cell subsets and natural killer-like T-cell populations in benign and neoplastic B-cell proliferations vary based on clinicopathologic features. Hum. Pathol. 2011;42:679–687. doi: 10.1016/j.humpath.2010.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humpath.2010.07.023</ArticleId><ArticleId IdType="pmc">PMC3677227</ArticleId><ArticleId IdType="pubmed">21292303</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly-Rogers J., Madrigal-Estebas L., O’Connor T., Doherty D.G. Activation-Induced Expression of CD56 by T Cells Is Associated with a Reprogramming of Cytolytic Activity and Cytokine Secretion Profile In Vitro. Hum. Immunol. 2006;67:863–873. doi: 10.1016/j.humimm.2006.08.292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2006.08.292</ArticleId><ArticleId IdType="pubmed">17145366</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittet M.J., Speiser D.E., Valmori D., Cerottini J.-C., Romero P. Cutting Edge: Cytolytic Effector Function in Human Circulating CD8+ T Cells Closely Correlates with CD56 Surface Expression. J. Immunol. 2000;164:1148–1152. doi: 10.4049/jimmunol.164.3.1148.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.164.3.1148</ArticleId><ArticleId IdType="pubmed">10640724</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Acker H.H., Capsomidis A., Smits E.L., Van Tendeloo V.F. CD56 in the Immune System: More than a Marker for Cytotoxicity? Front. Immunol. 2017;8:892. doi: 10.3389/fimmu.2017.00892.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00892</ArticleId><ArticleId IdType="pmc">PMC5522883</ArticleId><ArticleId IdType="pubmed">28791027</ArticleId></ArticleIdList></Reference><Reference><Citation>Terrazzano G., Bruzzaniti S., Rubino V., Santopaolo M., Palatucci A.T., Giovazzino A., La Rocca C., de Candia P., Puca A., Perna F., et al. T1D progression is associated with loss of CD3+CD56+ regulatory T cells that control CD8+ T cell effector functions. Nat. Metab. 2020;2:142–152. doi: 10.1038/s42255-020-0173-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42255-020-0173-1</ArticleId><ArticleId IdType="pmc">PMC7272221</ArticleId><ArticleId IdType="pubmed">32500117</ArticleId></ArticleIdList></Reference><Reference><Citation>Leone S., Rubino V., Palatucci A.T., Giovazzino A., Carriero F., Cerciello G., Pane F., Ruggiero G., Terrazzano G. Bone marrow CD3+CD56+ regulatory T lymphocytes (TR3-56 cells) are inversely associated with activation and expansion of bone marrow cytotoxic T cells in IPSS-R very-low/low risk MDS patients. Eur. J. Haematol. 2022;109:398–405. doi: 10.1111/ejh.13822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.13822</ArticleId><ArticleId IdType="pmc">PMC9543123</ArticleId><ArticleId IdType="pubmed">35775392</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubino V., Leone S., Carriero F., Pane F., Ruggiero G., Terrazzano G. The potential etiopathogenetic role and diagnostic utility of CD3+CD56+ regulatory T lymphocytes in Myelodysplastic Syndromes. Eur. J. Haematol. 2023;110:578–579. doi: 10.1111/ejh.13931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.13931</ArticleId><ArticleId IdType="pubmed">36660793</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovazzino A., Leone S., Rubino V., Palatucci A.T., Cerciello G., Alfinito F., Pane F., Ruggiero G., Terrazzano G. Reduced regulatory T cells (Treg) in bone marrow preferentially associate with the expansion of cytotoxic T lymphocytes in low risk MDS patients. Br. J. Haematol. 2019;185:357–360. doi: 10.1111/bjh.15496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.15496</ArticleId><ArticleId IdType="pubmed">30010189</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubino V., Carriero F., Palatucci A.T., Giovazzino A., Leone S., Nicolella V., Calabrò M., Montanaro R., Brancaleone V., Pane F., et al. Adaptive and Innate Cytotoxic Effectors in Chronic Lymphocytic Leukaemia (CLL) Subjects with Stable Disease. Int. J. Mol. Sci. 2023;24:9596. doi: 10.3390/ijms24119596.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24119596</ArticleId><ArticleId IdType="pmc">PMC10253385</ArticleId><ArticleId IdType="pubmed">37298547</ArticleId></ArticleIdList></Reference><Reference><Citation>Vavilova J.D., Ustiuzhanina M.O., Boyko A.A., Streltsova M.A., Kust S.A., Kanevskiy L.M., Iskhakov R.N., Sapozhnikov A.M., Gubernatorova E.O., Drutskaya M.S., et al. Alterations in the CD56− and CD56+ T Cell Subsets during COVID-19. Int. J. Mol. Sci. 2023;24:9047. doi: 10.3390/ijms24109047.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24109047</ArticleId><ArticleId IdType="pmc">PMC10219320</ArticleId><ArticleId IdType="pubmed">37240393</ArticleId></ArticleIdList></Reference><Reference><Citation>Gozzi-Silva S.C., Oliveira L.D.M., Alberca R.W., Pereira N.Z., Yoshikawa F.S., Pietrobon A.J., Yendo T.M., de Souza Andrade M.M., Ramos Y.A.L., Brito C.A., et al. Generation of Cytotoxic T Cells and Dysfunctional CD8 T Cells in Severe COVID-19 Patients. Cells. 2022;11:3359. doi: 10.3390/cells11213359.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11213359</ArticleId><ArticleId IdType="pmc">PMC9659290</ArticleId><ArticleId IdType="pubmed">36359755</ArticleId></ArticleIdList></Reference><Reference><Citation>Scalia G., Raia M., Gelzo M., Cacciapuoti S., De Rosa A., Pinchera B., Scotto R., Giaccone A., Mormile M., Fabbrocini G., et al. Cytometric analysis of patients with COVID-19: What is changed in the second wave? J. Transl. Med. 2021;19:403. doi: 10.1186/s12967-021-03072-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-021-03072-1</ArticleId><ArticleId IdType="pmc">PMC8460184</ArticleId><ArticleId IdType="pubmed">34556132</ArticleId></ArticleIdList></Reference><Reference><Citation>Working Group on the Clinical Characterisation and Management of COVID19 infection A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect. Dis. 2020;20:e192–e197. doi: 10.1016/S1473-3099(20)30483-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30483-7</ArticleId><ArticleId IdType="pmc">PMC7292605</ArticleId><ArticleId IdType="pubmed">32539990</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurent P., Jolivel V., Manicki P., Chiu L., Contin-Bordes C., Truchetet M.E., Pradeu T. Immune-Mediated Repair: A Matter of Plasticity. Front. Immunol. 2017;8:454. doi: 10.3389/fimmu.2017.00454.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00454</ArticleId><ArticleId IdType="pmc">PMC5403426</ArticleId><ArticleId IdType="pubmed">28484454</ArticleId></ArticleIdList></Reference><Reference><Citation>Margraf A., Perretti M. Immune Cell Plasticity in Inflammation: Insights into Description and Regulation of Immune Cell Phenotypes. Cells. 2022;11:1824. doi: 10.3390/cells11111824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11111824</ArticleId><ArticleId IdType="pmc">PMC9180515</ArticleId><ArticleId IdType="pubmed">35681519</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiteside T.L. Human regulatory T cells (Treg) and their response to cancer. Expert Rev. Precis. Med. Drug Dev. 2019;4:215–228. doi: 10.1080/23808993.2019.1634471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23808993.2019.1634471</ArticleId><ArticleId IdType="pmc">PMC7500484</ArticleId><ArticleId IdType="pubmed">32953989</ArticleId></ArticleIdList></Reference><Reference><Citation>Piconese S., Walker L.S.K., Dominguez-Villar M. Editorial: Control of Regulatory T Cell Stability, Plasticity, and Function in Health and Disease. Front. Immunol. 2021;11:611591. doi: 10.3389/fimmu.2020.611591.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.611591</ArticleId><ArticleId IdType="pmc">PMC7873440</ArticleId><ArticleId IdType="pubmed">33584690</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi B.D., Gedeon P.C., Herndon J.E., 2nd, Archer G.E., Reap E.A., Sanchez-Perez L., Mitchell D.A., Bigner D.D., Sampson J.H. Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody. Cancer Immunol. Res. 2013;1:163. doi: 10.1158/2326-6066.CIR-13-0049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-13-0049</ArticleId><ArticleId IdType="pmc">PMC3932050</ArticleId><ArticleId IdType="pubmed">24570975</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>